Xeltis announced encouraging preliminary safety and patency data from clinical trials evaluating Xabg, its bioengineered coronary artery bypass conduit, in patients with multi-vessel atherosclerotic disease. Utilizing innovative supramolecular chemistry and electrospun nanofibers, Xeltis aims to create implants that restore vascular function through gradual tissue regeneration. Trials are ongoing in Europe and South America, positioning the company’s technology as a promising alternative in vascular surgery.